RxDoctor Payments Data

Feroz Padder, MD

Cardiovascular Disease · Laurel, MDNPI 1942291737

Payments from drug & device makers

$1,954in general payments, 2019–2025

Across 43 payments — averaging $45.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Pfizer$115
  • E.r. Squibb & Sons, L.L.C.$79
  • Novo Nordisk$66
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$60
  • Amgen$47
  • plus $147 from 6 others

What the payments were for

  • Travel & lodging$1,06054%
  • Food & beverage$89446%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,954 in reported general payments places this provider in the 50th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$416,938
Medicare patients
1,059
Services billed
3,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$116,652
EntrestoSacubitril/Valsartan36$64,952
JardianceEmpagliflozin15$25,893
XareltoRivaroxaban12$16,178
Repatha SureclickEvolocumab14$10,991
Metoprolol Succinate280$4,152
Atorvastatin Calcium318$4,075
Losartan Potassium173$1,895
Valsartan36$1,748
Amlodipine Besylate223$1,732
Hydralazine Hcl61$1,611
Rosuvastatin Calcium70$1,495
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,358
ClopidogrelClopidogrel Bisulfate102$1,349
Ezetimibe24$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$116,65297 claims
NovartisEntresto$29$64,95236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Laurel

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →